Anti-HMGB1 antibody [EPR3507] (Ab79823)
HMG1, HMGB1, High mobility group protein B1, High mobility group protein 1, HMG-1
用户验证的应用
推荐稀释比例
- IHC-P1/350 - 1/400 Perform heat-mediated antigen retrieval with Tris/EDTA buffer pH 9.0 before commencing with IHC staining protocol.
- WB1/10000 - 1/50000
- ICC/IF1/250
- Flow Cyt (Intra)1/30 ab172730 - Rabbit monoclonal IgG, is suitable for use as an isotype control with this antibody.
详细信息
背景信息
Anti-HMGB1 antibody [EPR3507] (ab79823) was developed by Abcam using patented rabbit monoclonal antibody technology and is validated for use in Flow Cyt (Intra), ICC/IF, IHC-P and WB. Anti-HMGB1 antibody [EPR3507] (ab79823) was first used in a scientific publication in 2011 and has been cited over 275 times in peer reviewed journals. It's performance in Western Blot in human, mouse and rat samples is trusted by the scientific community. Abcam's high quality manufacturing and validation processes ensure Anti-HMGB1 antibody [EPR3507] (ab79823) has high sensitivity and specificity alongside high lot-to-lot consistency and reproducibility. The specificity of Anti-HMGB1 antibody [EPR3507] (ab79823) has been confirmed by Western Blot testing in HMGB1 knockout HeLa cells ( ab255395 ). Anti-HMGB1 antibody [EPR3507] (ab79823) has 7 independent reviews from customers. Anti-HMGB1 antibody [EPR3507] (ab79823) specifically detects HMGB1 (UniProt ID: P09429; Molecular weight: 25kDa) and is sold in 100 µL and 1 mL selling sizes. Conjugation-ready, carrier free format available for antibody clone EPR3507 - ab216986. Antibody clone EPR3507 is also available pre-conjugated to a variety of labels for your convenience - Alexa Fluor ® 488, Alexa Fluor ® 647, HRP, Alexa Fluor ® 594, Alexa Fluor ® 405, Alexa Fluor ® 555, APC, PE ( ab195010, ab195011, ab195012, ab206894, ab206895, ab206896, ab225041, ab225042 ). HMGB1 promotes inflammation and tissue damage in diseases like sepsis, cancer and autoimmune disorders by acting as a damage-associated molecular pattern (DAMP) and activating immune responses. Patented technology Our RabMAb ® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb ® patents. What are the advantages of a recombinant monoclonal antibody? This product is a recombinant monoclonal antibody, which offers several advantages including - High batch-to-batch consistency and reproducibility - Improved sensitivity and specificity - Long-term security of supply - Animal-free batch production For more information, read more on recombinant antibodies.
文献引用 (360)
HMGB1 functions as a critical mediator of host defense at the gut mucosal barrier.
HMGB1 在肠道粘膜屏障中发挥着宿主防御的关键介质的作用。
Combined Photothermal and mTOR-Targeted Therapy Overcomes Immune Evasion and Enhances Checkpoint Blockade Efficacy in Metastatic Triple-Negative Breast Cancer.
光热疗法与 mTOR 靶向疗法相结合可克服免疫逃逸并增强转移性三阴性乳腺癌的检查点阻断疗效。
Engineering a modular FAP-targeting ferritin-based drug nanocarrier for enhanced glioblastoma theranostics.
构建模块化的 FAP 靶向铁蛋白基药物纳米载体,以增强胶质母细胞瘤的诊疗效果。
Immune remodeling via mitochondria-dependent STING activation enhances cabozantinib response in hepatocellular carcinoma.
通过线粒体依赖性 STING 激活进行免疫重塑可增强卡博替尼对肝细胞癌的疗效。
Galangin-loaded biomimetic dendritic cells membrane nanovaccine reprograms the ovarian cancer microenvironment via Stat3/IDO1/AhR axis to boost immunotherapy.
载有 Galangin 的仿生树突状细胞膜纳米疫苗通过 Stat3/IDO1/AhR 轴重编程卵巢癌微环境,从而增强免疫疗法。
Biomimetic nanovesicle with tri-pronged immune amplification for efficient photo-immunotherapy against triple-negative breast cancer.
具有三重免疫放大作用的仿生纳米囊泡,可有效用于治疗三阴性乳腺癌的光免疫疗法。
Metformin glycyrrhetinic acid binary injectable hydrogel for synergistic tumor immunotherapy via spatiotemporal microenvironment remodeling.
二甲双胍甘草次酸二元注射水凝胶通过时空微环境重塑实现协同肿瘤免疫治疗。
Promoting the nuclear retention of HMGB1 attenuates astrocyte senescence.
促进 HMGB1 在细胞核内的滞留可减轻星形胶质细胞衰老。
New Insights into Atonic Postpartum Hemorrhage: Animal Model Construction Based on Placental Nanodelivery Systems.
对子宫收缩乏力性产后出血的新认识:基于胎盘纳米递送系统的动物模型构建。
Novel anti-HER2 nanobody-drug conjugates with enhanced penetration of solid tumor and BBB, reduced systemic exposure and superior antitumor efficacy.
新型抗 HER2 纳米抗体-药物偶联物,具有增强的实体瘤和血脑屏障渗透性、降低的全身暴露和优异的抗肿瘤疗效。
- 1
- 2
- 3
- 4
- 5
- 6
- 36